Explore every episode of the podcast CME in Minutes: Education in Primary Care

Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.

Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/CKZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses patient-centered approaches to the diagnosis and treatment of biliary tract cancer. Upon completion of this activity, participants should be better able to: Recognize the importance of achieving an accurate diagnosis of biliary tract cancer (BTC); Outline strategies for reaching a diagnosis of BTC, including cholangiocarcinoma; and Describe patient-centered approaches to enhance outcomes for patients undergoing a diagnostic work-up for BTC.

Please visit answersincme.com/UWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses chemoimmunotherapy treatment of advanced squamous cell non-small cell lung cancer without molecular alterations. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of approved chemoimmunotherapy combinations for treatment of patients with advanced squamous cell non-small cell lung cancer (NSCLC) without molecular alterations; Review clinical factors for individualizing first-line treatment of patients with advanced squamous cell NSCLC; and Identify real-world factors that impact treatment selection for patients with advanced squamous cell NSCLC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/KQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in narcolepsy discusses the evaluation and treatment of patients with narcolepsy and cardiovascular disease. Upon completion of this activity, participants should be better able to: Explain the rationale for evaluating patients with narcolepsy for cardiovascular (CV) risk; Review the clinical profiles of guideline-recommended treatment options for narcolepsy, including impact on CV risk; and Outline real-world clinical strategies to optimize long-term management of patients with narcolepsy, including those at risk of CV disease.

Please visit answersincme.com/AEP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses strategies to integrate novel anti-CD38 monoclonal antibody (mAb)-based triplet regimens into care plans for patients with early relapse multiple myeloma (MM). Upon completion of this activity, participants should be better able to: Review the latest evidence-based guideline recommendations for the treatment of early relapse MM; Outline the clinical implications of the latest evidence for anti-CD38 mAb-based triplet regimens in the treatment of early relapse MM; and Identify strategies to optimally integrate novel anti-CD38 mAb-based triplet regimens into treatment plans for patients with early relapse MM.

Please visit answersincme.com/VMK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the use of novel therapies for patients with transfusion-dependent beta thalassemia. Upon completion of this activity, participants should be better able to: Describe the limitations of ongoing transfusions for patients with transfusion-dependent beta thalassemia (TDT); Review the evidence on novel therapies for TDT; and Outline shared decision-making strategies for the potential use of novel therapies for patients with TDT.

Please visit answersincme.com/XFG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in vascular neurology discusses the data and the implications for inhibiting coagulation factor XIa (FXIa) as a therapeutic option in stroke prevention. Upon completion of this activity, participants should be better able to: Identify the rationale for inhibiting FXIa as a therapeutic option in stroke prevention; Describe the latest clinical data for oral FXIa inhibitors in stroke prevention; and Review the implications of the latest FXIa inhibitor data for the future of stroke prevention.

Please visit answersincme.com/SWS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver cancer discusses emerging transarterial chemoembolization (TACE) plus immunotherapy–based combinations in intermediate-stage hepatocellular carcinoma (iHCC). Upon completion of this activity, participants should be better able to: Identify the limitations of currently available therapeutic approaches for patients with locoregional therapy–eligible, unresectable hepatocellular carcinoma (HCC); Describe the clinical significance of combination therapies that involve transarterial chemoembolization (TACE) and immunotherapy for patients with intermediate HCC (iHCC); and Review clinical strategies to integrate TACE plus immunotherapy–based combination regimens into the treatment paradigm for patients with iHCC, based on the preliminary data.

Please visit answersincme.com/TSH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of metastatic colorectal cancer (mCRC) discuss sequencing strategies to enhance patient quality of life during later-line treatment. Upon completion of this activity, participants should be better able to: Describe the latest data for later-line treatment sequencing for patients with mCRC; Outline evidence-based strategies to optimally sequence later-line treatment options for mCRC; and Explain tactics for addressing quality of life and survivorship with patients in later lines of treatment for mCRC.

Please visit answersincme.com/CGH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses evidence and guidance on using multimodal approaches for managing patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Upon completion of this activity, participants should be better able to: Identify the continued needs with the currently available therapies for inoperable CTEPH; Review the clinical evidence for multimodal approaches in inoperable CTEPH in the context of currently available therapies; and Outline clinical factors that may facilitate optimal therapeutic selection for patients with inoperable CTEPH.

Please visit answersincme.com/NVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics and immunology discusses the continued burden of respiratory syncytial virus (RSV) in infants and strategies to increase vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the rationale for respiratory syncytial virus (RSV) prevention in infants; Review the clinical profiles of national guideline-recommended RSV prophylactic agents in infants; and Outline patient-centered strategies to optimize the uptake of RSV prophylactic options in infants.

Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.

Please visit answersincme.com/YFE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses populations at high risk for cervical cancer and how to apply clinical advances and evolve care in locally advanced disease. Upon completion of this activity, participants should be better able to: Identify populations at high risk of developing cervical cancer; Describe strategies to improve uptake of routine screening for cervical cancer, particularly in high-risk populations; and Outline clinical advances that may evolve the care of patients with newly diagnosed high-risk locally advanced cervical cancer.

Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity, participants should be better able to: Recognize the rationale for testing for HER2 status in patients with pretreated advanced gastric cancer; Translate the latest clinical evidence on testing to guide selection of HER2-targeted treatments for advanced gastric cancer; and Outline practical multidisciplinary approaches to optimize personalized care of patients with previously treated HER2-positive advanced gastric cancer to enhance health-related quality of life.

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/FPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the diagnosis and pharmacological management of Lennox-Gastaut syndrome (LGS), and is joined by a patient advocate to discuss the impact of LGS on patients and their families. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of LGS on the lives of patients with the disease and their families; Outline strategies to accurately diagnose LGS in children and adults; and Describe the pharmacological treatment options available for patients with LGS.

Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.

Please visit answersincme.com/MVB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology and a patient advocate discuss strategies to optimize care for patients with metastatic breast cancer using antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Identify the rationale for targeted antibody-drug conjugates (ADCs) in the treatment of patients with metastatic breast cancer (mBC); Review strategies to enhance safety of the available ADCs for the treatment of mBC; and Outline patient-focused strategies to optimize the use of ADCs in appropriate patients with mBC.

Please visit answersincme.com/PKW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses guideline and treatment updates for the management of hypertrophic cardiomyopathy, and the clinical implications of recent data on novel cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Outline the latest guideline updates for diagnosis and treatment of obstructive HCM; Review strategies to facilitate the early diagnosis of obstructive HCM; and Recognize the clinical significance of the latest data on cardiac myosin inhibitors for the treatment of obstructive HCM.

Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.

Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices for integrating biomarker testing into practice for stage I to III NSCLC; Describe the clinical profiles of current and emerging therapeutic approaches for the management of stage I to III NSCLC; and Outline multidisciplinary strategies to optimize the integration of a targeted approach into clinical practice for patients with stage I to III NSCLC.

Please visit answersincme.com/WMY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. Upon completion of this activity, participants should be better able to: Define “clinical remission” of asthma; and Review the impact of approved biologics for the treatment of patients with T2 asthma on clinical remission; Outline strategies for incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.

Please visit answersincme.com/UYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology and digestive oncology discusses guidance for use of TKI therapy in advanced hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Describe evidence for the optimal use of tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC); Identify patient- and disease-based factors which guide the use of TKI therapy for the treatment of advanced HCC; and Outline strategies to develop personalized treatment plans to maximize clinical outcomes using TKI therapies in the treatment of advanced HCC.

Please visit answersincme.com/DMQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the role of CELMoDs in overcoming IMiD resistance in earlier lines of therapy for multiple myeloma. Upon completion of this activity, participants should be better able to: Explain the biologic rationale for investigating novel CELMoDs in earlier lines of therapy in patients with multiple myeloma (MM); Review the clinical significance of late-stage trials of emerging CELMoDs in the maintenance and earlier-relapse settings in patients with MM; and Outline the clinical considerations for integrating novel CELMoDs in the maintenance and earlier-relapse settings in the future treatment landscape of MM.

Please visit answersincme.com/JPC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies to optimize the management of patients with moderate to severe hand and foot atopic dermatitis (AD), including treatment with novel systemic therapies. Upon completion of this activity, participants should be better able to: Describe the impacts of moderate to severe hand and foot AD on patients’ quality of life; Review the implications of the clinical data for novel systemic therapies in patients with moderate to severe hand and foot AD; and Outline practical, personalized approaches to optimize management of patients with moderate to severe hand and foot AD.

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/YCT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with asthma who may benefit from treatment intensification with biologic therapy; Outline the clinical impact of add-on biologics approved for the treatment of pediatric patients with moderate to severe asthma; and Identify patient-centered strategies to optimize outcomes for pediatric patients with inadequately controlled moderate to severe asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.

Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy in the neoadjuvant treatment of early HR-positive, HER2-negative breast cancer; Identify the clinical implications of the latest data for neoadjuvant treatment with immunotherapy plus chemotherapy regimens in early HR-positive, HER2-negative breast cancer; Describe the role that neoadjuvant, immunotherapy-containing regimens might play in the future management of patients with early HR-positive, HER2-negative breast cancer, including high risk patients

Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care

Please visit answersincme.com/PES860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary disease discusses the implications of the latest evidence on biologic therapies targeting type 2 inflammation for the treatment of chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD); Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations; Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/UYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses novel treatment options being investigated for patients with Alzheimer’s disease psychosis (ADP). Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in managing patients with Alzheimer’s disease psychosis (ADP); Review the rationale for using therapies with novel mechanisms for the treatment of patients with ADP; Describe the implications of the latest data on novel therapies for managing patients with ADP.

Please visit answersincme.com/VAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women's health and menopause discusses novel, nonhormonal strategies to treat vasomotor symptoms (VMS) associated with menopause. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel nonhormonal therapies in the treatment of VMS associated with menopause; Review the clinical profiles of approved and emerging novel nonhormonal treatments of VMS associated with menopause; Outline patient-centered, evidence-based strategies to optimize the treatment of common menopausal symptoms

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

Please visit answersincme.com/DKN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses antipsychotics in schizophrenia. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia; Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia; and Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia.

Please visit answersincme.com/WSK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Evan S. Dellon, MD, MPH, an expert in esophageal disease, discusses best practices to facilitate timely diagnosis of eosinophilic esophagitis (EoE) through symptom recognition and referral at the emergency department. Upon completion of this activity, participants should be better able to: Recognize the consequences of untreated eosinophilic esophagitis (EoE), including the burden of food impaction; Identify best practices to facilitate the timely diagnosis and management of EoE through symptom recognition and referral; and Review the available therapeutic modalities for EoE that support the need for timely referral. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; and Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC.

Please visit answersincme.com/BHU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lymphoma discusses the treatment landscape for CD30-positive peripheral T-cell lymphoma (PTCL). Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations for frontline treatment of PTCL; Describe the clinical evidence informing the use of CD30-directed therapy in frontline treatment of PTCL; and Outline considerations to optimize outcomes with CD30-directed therapy for frontline treatment of patients with PTCL.

Please visit answersincme.com/860/93496951-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the clinical implications of the latest data for HER2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC; and Describe practical, data-driven approaches to effectively integrate current and emerging ADCs into the management of advanced NSCLC.

Please visit answersincme.com/860/94256783-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the clinical significance of the latest efficacy and safety data for perioperative immunotherapeutic regimens for resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the significance of the latest clinical data of perioperative immunotherapeutic approaches in patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

Please visit answersincme.com/KWX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in bipolar disorder and a patient advocate discuss patient-centered care for people with bipolar I. Upon completion of this activity, participants should be better able to: Identify patient-centered strategies to optimize the timely diagnosis of bipolar I disorder (BD-I); Review goal-oriented therapeutic approaches that address the personalized needs of patients with BD-I; and Outline strategies to ensure the delivery of patient-centric care that incorporates patients’ wishes, values, priorities, and goals.

Please visit answersincme.com/860/94256783-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

Please visit answersincme.com/GCB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of diabetic macular edema (DME) discuss the primary care physician (PCP) and ophthalmologist’s partnership in the care for patients with DME and optimizing treatment with VEGF-targeting agents. Upon completion of this activity, participants should be better able to: Explain how extending treatment intervals for DME can improve patient satisfaction and treatment persistence with intravitreal anti-VEGF therapy; Discuss the clinical benefits of longer-acting intravitreal anti-VEGF agents in the treatment of DME; Describe multidisciplinary care plans that improve the long-term treatment outcomes of patients with patients with DME; and Outline strategies for optimizing DME outcomes in the primary care setting. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/YZW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses biologic therapy for prurigo nodularis, and a patient presents her perspective. Upon completion of this activity, participants should be better able to: Identify the therapeutic needs of patients with PN; Review the evidence for current and emerging biologic treatments for PN; and Outline how to integrate biologic therapies into the care of patients with PN.

Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.

Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.